Royalty Pharma Reports Q3 Revenue Growth to $690 Million
Royalty Pharma (RPRX) announced its third-quarter financial results, reporting revenue of $690 million, which represents a 13.3% increase compared to the same period last year. The company demonstrated progress in managing its balance sheet by reducing total debt from $9.2 billion to $8.8 billion. As of September 30, 2024, the company maintained a liquidity position with $514 million in cash and cash equivalents. The results reflect steady top-line growth alongside ongoing efforts to deleverage its significant debt load.
Tickers: $RPRX
Topics: cash position debt reduction quarterly earnings revenue growth